Several other equities analysts have also recently weighed in on the stock. Chardan Capital reaffirmed a buy rating on shares of CRISPR THERAPTC in a research note on Monday, August 14th. Oppenheimer Holdings, Inc. reiterated a market perform rating on shares of CRISPR THERAPTC in a research note on Tuesday, July 18th. Cann assumed coverage on shares of CRISPR THERAPTC in a research note on Monday, July 17th. They issued a market perform rating for the company. Finally, SunTrust Banks, Inc. assumed coverage on shares of CRISPR THERAPTC in a research note on Thursday, July 13th. They issued a hold rating and a $16.00 target price for the company. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. CRISPR THERAPTC has an average rating of Buy and a consensus price target of $23.08.
Shares of CRISPR THERAPTC (CRSP) opened at 19.15 on Friday. The stock has a 50 day moving average of $18.56 and a 200-day moving average of $17.82. The firm’s market capitalization is $777.32 million. CRISPR THERAPTC has a 52 week low of $11.63 and a 52 week high of $25.00.
CRISPR THERAPTC (NASDAQ:CRSP) last issued its quarterly earnings results on Thursday, August 10th. The company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.06. The company had revenue of $3.60 million during the quarter, compared to analysts’ expectations of $3.29 million. CRISPR THERAPTC had a negative net margin of 406.61% and a negative return on equity of 47.46%. The firm’s quarterly revenue was up 350.0% compared to the same quarter last year. Equities analysts anticipate that CRISPR THERAPTC will post ($2.43) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Barclays PLC Reiterates “Buy” Rating for CRISPR THERAPTC (CRSP)” was reported by BBNS and is owned by of BBNS. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://baseballnewssource.com/markets/barclays-plc-reiterates-buy-rating-for-crispr-theraptc-crsp/1623219.html.
In related news, Director Kurt Von Emster sold 3,150 shares of the firm’s stock in a transaction on Monday, August 21st. The shares were sold at an average price of $18.52, for a total value of $58,338.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Rodger Novak sold 18,470 shares of the firm’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $20.76, for a total transaction of $383,437.20. Following the completion of the transaction, the chief executive officer now directly owns 1,148,007 shares of the company’s stock, valued at $23,832,625.32. The disclosure for this sale can be found here. Insiders sold 827,921 shares of company stock valued at $15,063,254 over the last three months. 39.98% of the stock is owned by company insiders.
Several large investors have recently added to or reduced their stakes in the stock. ARK Investment Management LLC bought a new position in shares of CRISPR THERAPTC in the second quarter valued at $206,000. Vanguard Group Inc. acquired a new stake in CRISPR THERAPTC during the 2nd quarter valued at $273,000. Wells Fargo & Company MN lifted its holdings in CRISPR THERAPTC by 459.7% during the 2nd quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock valued at $128,000 after purchasing an additional 6,560 shares during the last quarter. IHT Wealth Management LLC acquired a new stake in CRISPR THERAPTC during the 1st quarter valued at $110,000. Finally, Credit Suisse AG acquired a new stake in CRISPR THERAPTC during the 1st quarter valued at $1,742,000. 23.90% of the stock is owned by institutional investors and hedge funds.
CRISPR THERAPTC Company Profile
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for CRISPR THERAPTC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR THERAPTC and related companies with our FREE daily email newsletter.